MMF to EC-MPS conversion: What makes the difference? [1]

Liver Transplantation

Volumn 13, Issue 5, 2007, Pages 773-774

  Schmidt, Hartmut ^a   Brockmann, Jens ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FAT INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY TRANSPLANTATION; LETTER; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; RETREATMENT; TABLETS, ENTERIC-COATED;

EID: 34249075713     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21101     Document Type: Letter

References (5)

1. Dumortier J, Gagnieu M-C, Salandre J, Guillaud O, Guillem. P, Adham M, et al. Conversion from mycophenolate mofetfl to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transp] 2006;12:1342-1346.
2. Bullingham P, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-455.
3. Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 2000;14:179-188.
4. Budde K, Curtis J, Knoll G, Chan L, Neumayer H-H, Seifu Y, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2003;4:237-243.
5. Myfortic US prescribing information 180/-360 mg delayed-release tablets. Feb 2004. MS 04/4.2, Art-Nr.:89645.